°©Àf¤£¬O¦ºªº¡B¦Ó¬O¬¡ªº²Õ´¡A¦b§¹¦¨µo¨|ªº¦¨¦~¤H¡A¨Å骺¨C¤Ñ¾Þ§@·|¦b°íµwªº°©Àf°µ¦¨·L²Óªº¿i·l¡A¤HÅ馳¨â²Õ¨ã¦³¯S®í¥\¯àªº²ÓM°õ¦æ׸ɪº¤u§@¡G¡u»k°©²ÓM¡v(osteoclast)±N·lÃa©Î¯Ü®zªº°©½è¤Æ¸Ñ¡AµM«á¡u³y°©²ÓM¡v(osteoblast)±N¿ò¤Uªºíá»Ø¶ñ¸É¡B§Î¦¨·sªº°©¡C³oÓ¨â¨B¹Lµ{ºÙ¬°¡u°©«¶ì¡v(bone remodelling)¡A¦b°·±dªº¦~«C¦¨¦~¤H¡A¨C¤@Ó°©«¶ì©P´Á¬ù¬°¤T¦Ü¥|Ó¤ë¡A¤£¹LÀHµÛ¦~ÄÖªº¼Wªø¡A»k°©²ÓM©M³y°©²ÓM³vº¥¥¢¥h¨ó½Õ¥\¯àªº®Ä²v¡A°µ¦¨»k°©²ÓM¤Æ¸Ñ¦ÑÃaªº°©½è¤ñ³y°©²ÓM©Ò¯à««Øªº·s°©§Ö¡C¦¹¥~·í¤H¦Ñ¤Æ¡A§l¦¬¶t½è©M¨ä¥LÀç¾i¯Àªº¯à¤O¤]³vº¥´î®z¡F¦b¾Ö¦³±j°·°©Àfªº¤H¡A§l¦¬¾A¶qªº¶t½è¯à¥O°©«¶ì«O«ù¥¿Å¡C¦b¦Ñ¦~¤H¡A§l¦¬¾A¶qªº¶t½è¯à´îºC°©½èªº¬y¥¢©M´î§C°©§éªº·ÀI¡F¨ä¹ê¡A¶t¬O¤HÅ餺³ÌÂ×´IªºÄqª«½è¡A¤HÅ餺¶W¹L¦Ê¥÷¤§¤E¤Q¤Eªº¶t¬OÀx¦s¦b°©Àf¤Î¤ú¾¦¡B¨Ã¤ä¼µµÛ¥¦Ìªºµ²ºc¡C¦¹¥~¶t¦b¦Ù¦×¥\¯à¡B¯«¸g°T¸¹¶Ç»¼©M¤º¤Àªc³£¾á·í«nªº¨¤¦â¡C¹L¶qªº¶t«o·|¬°¨Åé±a¨Ó¤£¨}ªº¼vÅT¡A¦å²G¤º¶tªº¤ô¥¹L°ª(°ª¦å¶t¯ghypercalcemia)·|¾ÉPµÇ¥\¯à¤£¥þ¡B¦åºÞ¤Î³n²Õ´¶t¤Æ¡B°ª§¿¶t¯g¤ÎµÇµ²¥Ûµ¥¡CÁöµM°ª¦å¶t¯g¥i¯à¬O¶i¹¶t§t¶q«D±`°ªªº¶¼¹¤Þ°_¡A¦ý¤j¦h¼Æ«o¬O¦]ìµo©Ê¥Òª¬®Ç¸¢¥\¯à¤®¶i(primary hyperparathyroidism)©ÎÀù¯f¤Þ°_ªº¡CÄá¨ú¹L¶qªº¶t·|¾ÉP«K¯¦¡BµÇµ²¥Û¡B«e¦C¸¢Àù¡B¤ßŦ¯fµ¥¡A¤Î§«Ãª¨ä¥LÀç¾i¯À(¥]¬AÅK¡B¾Nµ¥)ªº§l¦¬¡C¬ã¨sÅã¥Ü¡A³æ±q¶¼¹Äá¨ú¹L¶qªº¶t¬O¤Ö¨£ªº¡AÄá¨ú¹L¶qªº¶t³q±`¬O¦]ªA¥Î¶t¸É¥R¾¯¤Þ°_ªº¡C ¬ü°êÂå¾Ç¬ã¨s©Ò»{¬°Äá¨ú¦h©ó«Øij¨C¤ÑÄá¨ú¶qªº¶t¤£·|¬°°·±d±a¨ÓÃB¥~ªº¦n³B¡A¨Ã«ØijÀ³¨î¶tªºÄá¨ú¶q§C©ó¨C¤Ñ³Ì°ªÄá¨ú¶q¡B¥H¨¾¥X²{¤£¨}°Æ§@¥Î¡A¥[®³¤j½Ã¥Í³¡¥ç±Ä¥Î³oӼзǡC¥[®³¤j°©½è²¨ÃP¨ó·|±N¨C¤ÑªºÄá¨ú¶q²¤Æ¬°¡G(¤@)¤Q¤E¦Ü¤¤Q·³¡G1000²@§J¡F(¤G)¤¤Q·³¥H¤W¡G1200²@§J¡F(¤T)¤Q¤K·³¥H¤WÃh¥¥¤Î÷¨Åªº°ü¤k¡G1000²@§J¡C ¬ü°êÂå¾Ç¬ã¨s©Ò(U. S. Institute of Medicine ²ºÙIOM)©ó2010¦~11¤ë30¤é¤½§G³Ì·s¶tªº¡u¿¯¹Àç¾i¯ÀÄá¨ú°Ñ¦Ò¶q¡v(Dietary Reference Intakes DRIs)©M©w¥X³Ì·sªº¡u¨C¤Ñ³Ì°ªÄá¨ú¶q¡v(Tolerable Upper Intake Level per day ²ºÙUL).
|
|
|